Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) Print E-mail
By M.E.Garza   
Friday, 12 June 2009 20:48

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and premarin the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.

Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
We also have an alternate feed available if you find that this feed is slow to load.

TRT: Approximately 45 Minutes

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus


BioMedReports New Technology Aims to Empower First Responders Treating Victims of Carbon Monoxide Poisonings: http://t.co/8WbX5u6L1X $MNLIF
BioMedReports Actinium Targets Fourth Quarter IND Filing for Iomab-B Subsequent to Pre-IND Meeting With FDA: http://t.co/pJuOoqz4Fz $ATNM
BioMedReports Abeona Announces License for Next Generation AAV Delivery Vector for Fanconi Anemia and Rare Blood Disease: http://t.co/3I94Yt3JLT $ABEO